Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of north east Japan study group 002 trial

Satoshi Oizumi, Kunihiko Kobayashi, Akira Inoue, Makoto Maemondo, Shunichi Sugawara, Hirohisa Yoshizawa, Hiroshi Isobe, Masao Harada, Ichiro Kinoshita, Shoji Okinaga, Terufumi Kato, Toshiyuki Harada, Akihiko Gemma, Yasuo Saijo, Yuki Yokomizo, Satoshi Morita, Koichi Hagiwara, Toshihiro Nukiwa

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background. For non-small cell lung cancer (NSCLC) Patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progressionfree survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. This report describes the quality of life (QoL) analysis of that study. Methods. Chemotherapy-naïve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). Patient QoL was assessed weekly using the Care Notebook, and the primary endpoint of the QoL analysis was time to deterioration from baseline on each of the physical, mental, and life well-being QoL scales. Kaplan- Meier probability curves and log-rank tests were employed to clarify differences. Results. QoL data from 148 patients (72 in the gefitinib arm and 76 in the carboplatin plus paclitaxel arm) were analyzed. Time to defined deterioration in physical and life well-being significantly favored gefitinib over chemotherapy (hazard ratio [HR] of time to deterioration, 0.34; 95% confidence interval [CI], 0.23- 0.50; p <.0001 and HR, 0.43; 95% CI, 0.28 - 0.65; p <.0001, respectively). Conclusion. QoL was maintained much longer in patients treated with gefitinib than in patients treated with standard chemotherapy, indicating that gefitinib should be considered as the standard first-line therapy for advanced EGFR-mutated NSCLC in spite of no survival advantage.

Original languageEnglish
Pages (from-to)863-870
Number of pages8
JournalOncologist
Volume17
Issue number6
DOIs
Publication statusPublished - 2012

Keywords

  • EGFR
  • Epidermal growth factor receptor
  • Gefitinib
  • Lung carcinoma
  • QoL
  • Quality of life
  • TKI
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of north east Japan study group 002 trial'. Together they form a unique fingerprint.

  • Cite this

    Oizumi, S., Kobayashi, K., Inoue, A., Maemondo, M., Sugawara, S., Yoshizawa, H., Isobe, H., Harada, M., Kinoshita, I., Okinaga, S., Kato, T., Harada, T., Gemma, A., Saijo, Y., Yokomizo, Y., Morita, S., Hagiwara, K., & Nukiwa, T. (2012). Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of north east Japan study group 002 trial. Oncologist, 17(6), 863-870. https://doi.org/10.1634/theoncologist.2011-0426